Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis

I. Spicka, P. Moreau, TG. Martin, T. Facon, G. Martinez, A. Oriol, Y. Koh, A. Lim, G. Mikala, L. Rosiñol, M. Yağci, M. Cavo, ML. Risse, G. Asset, S. Macé, H. van de Velde, K. Yong

. 2022 ; 109 (5) : 504-512. [pub] 20220818

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22032906

INTRODUCTION: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. This prespecified subgroup analysis of IKEMA examined efficacy and safety in patients with high-risk cytogenetics. METHODS: High-risk cytogenetics was assessed by central laboratory and patients were classified as high risk if abnormalities were present in ≥1 of the following: del(17p): 50% cutoff; t(4;14), and/or t(14;16): 30% cutoff. RESULTS: Of the randomized patients, 23.5% (Isa-Kd) and 25.2% (Kd) had ≥1 high-risk chromosomal abnormality. A PFS benefit was seen in favor of Isa-Kd for patients with standard-risk (HR 0.440; 95% CI 0.266-0.728) and high-risk cytogenetics (HR 0.724; 95% CI 0.361-1.451). Grade ≥3 treatment-emergent adverse events (TEAEs) were more common with Isa-Kd (85.7%) versus Kd (63.3%) in patients with high-risk cytogenetics; however, the incidence of serious TEAEs (64.3% vs. 66.7%) was similar. CONCLUSIONS: Isa-Kd is a new treatment option for the difficult-to-treat subgroup of patients with relapsed MM and high-risk cytogenetics.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032906
003      
CZ-PrNML
005      
20230131151316.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.13835 $2 doi
035    __
$a (PubMed)35871357
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Spicka, Ivan $u 1st Department of Medicine-Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic
245    10
$a Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis / $c I. Spicka, P. Moreau, TG. Martin, T. Facon, G. Martinez, A. Oriol, Y. Koh, A. Lim, G. Mikala, L. Rosiñol, M. Yağci, M. Cavo, ML. Risse, G. Asset, S. Macé, H. van de Velde, K. Yong
520    9_
$a INTRODUCTION: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. This prespecified subgroup analysis of IKEMA examined efficacy and safety in patients with high-risk cytogenetics. METHODS: High-risk cytogenetics was assessed by central laboratory and patients were classified as high risk if abnormalities were present in ≥1 of the following: del(17p): 50% cutoff; t(4;14), and/or t(14;16): 30% cutoff. RESULTS: Of the randomized patients, 23.5% (Isa-Kd) and 25.2% (Kd) had ≥1 high-risk chromosomal abnormality. A PFS benefit was seen in favor of Isa-Kd for patients with standard-risk (HR 0.440; 95% CI 0.266-0.728) and high-risk cytogenetics (HR 0.724; 95% CI 0.361-1.451). Grade ≥3 treatment-emergent adverse events (TEAEs) were more common with Isa-Kd (85.7%) versus Kd (63.3%) in patients with high-risk cytogenetics; however, the incidence of serious TEAEs (64.3% vs. 66.7%) was similar. CONCLUSIONS: Isa-Kd is a new treatment option for the difficult-to-treat subgroup of patients with relapsed MM and high-risk cytogenetics.
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a dexamethason $x škodlivé účinky $7 D003907
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x diagnóza $x farmakoterapie $x genetika $7 D009101
650    _2
$a oligopeptidy $7 D009842
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moreau, Philippe $u University of Nantes, Nantes, France $1 https://orcid.org/0000000317808746
700    1_
$a Martin, Thomas G $u University of California San Francisco, San Francisco, California, USA
700    1_
$a Facon, Thierry $u Department of Haematology, Lille University Hospital, Lille, France
700    1_
$a Martinez, Gracia $u Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
700    1_
$a Oriol, Albert $u Hematology Department, Institut Català d'Oncologia and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain $1 https://orcid.org/0000000168042221
700    1_
$a Koh, Youngil $u Seoul National University Hospital, Seoul, South Korea
700    1_
$a Lim, Andrew $u Austin and Repatriation Medical Center, Heidelberg, Victoria, Australia
700    1_
$a Mikala, Gabor $u Department of Hematology and Stem Cell Transplantation, National Institute for Hematology and Infectious Diseases, South Pest Central Hospital, Budapest, Hungary
700    1_
$a Rosiñol, Laura $u Hospital Clinic, IDIBAPS, Barcelona, Spain
700    1_
$a Yağci, Münci $u Gazi University, Ankara, Turkey
700    1_
$a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy $u Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
700    1_
$a Risse, Marie-Laure $u Sanofi, R&D, Vitry-Sur-Seine, France
700    1_
$a Asset, Gaëlle $u Sanofi, R&D, Chilly-Mazarin, France
700    1_
$a Macé, Sandrine $u Sanofi, R&D, Vitry-Sur-Seine, France
700    1_
$a van de Velde, Helgi $u Sanofi, Cambridge, Massachusetts, USA
700    1_
$a Yong, Kwee $u Department of Haematology, University College Hospital, London, UK
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 109, č. 5 (2022), s. 504-512
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35871357 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151312 $b ABA008
999    __
$a ok $b bmc $g 1891577 $s 1184241
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 109 $c 5 $d 504-512 $e 20220818 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Archiving options